Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
82 hedge funds and large institutions have $362M invested in Marinus Pharmaceuticals, Inc in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 80 → 82 (+2)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
36% less capital invested
Capital invested by funds: $563M → $362M (-$202M)
41% less call options, than puts
Call options by funds: $3.35M | Put options by funds: $5.66M
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
+$5.84M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.72M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$5.1M |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$2.75M |
| 5 |
JP Morgan Chase
New York
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Scion Asset Management
Saratoga,
California
|
-$11.2M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.93M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.25M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.53M |
MRNS Hedge Fund Activity: Q3 2021 in Review
82 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2021, worth a combined $362M — down 36% from $563M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MRNS positions and 8 closed out — a net gain of 2 holders — while 20 added to existing stakes and 23 trimmed.
The largest buyer was Jefferies Group, adding an estimated $5.84M. The largest seller was Scion Asset Management, exiting entirely with an estimated $11.2M sold.
- 82 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $362M of Marinus Pharmaceuticals, Inc stock for Q3 2021, down 36% quarter-over-quarter.
- 10 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2021 and 8 closed out, a net change of +2 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2021 was Jefferies Group, an estimated $5.84M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2021 was Scion Asset Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2021.